Loading
TCF3 (Transcription factor E2-alpha) is a protein that switches other genes on and off. The public catalogues list it as a biomarker and a fusion partner, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Leukaemia, Non-Hodgkin lymphoma, Lung cancer and 3 more.
Transcriptional regulator involved in the initiation of neuronal differentiation and mesenchymal to epithelial transition. Heterodimers between TCF3 and tissue-specific basic helix-loop-helix (bHLH) proteins play major roles in determining tissue-specific cell fate during embryogenesis, like muscle or early B-cell differentiation. Together with TCF15, required for the mesenchymal to epithelial transition.
CIViC holds 1 clinical evidence item and 0 assertions across 1 variant. Open Targets scores its association with cancer at 0.65 (direct and indirect evidence; datatypes literature 0.96, genetic association 0.00, somatic mutation 0.83).
In plain words · TCF3 (Transcription factor E2-alpha) is a protein that switches other genes on and off. The public catalogues list it as a biomarker and a fusion partner, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Leukaemia, Non-Hodgkin lymphoma, Lung cancer and 3 more.
TCF3 (Transcription factor E2-alpha) is a protein that switches other genes on and off. The public catalogues list it as a biomarker and a fusion partner, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Leukaemia, Non-Hodgkin lymphoma, Lung cancer and 3 more.
Transcriptional regulator involved in the initiation of neuronal differentiation and mesenchymal to epithelial transition.
No product in this corpus aims at TCF3 yet. Transcription factors have no pocket to plug, so drugs either degrade them or block the partner protein they need to dock on DNA.
Tumour-specific alteration: the catalogues call it a fusion partner (UniProt records a translocation); what a medicine would aim at or exploit is the altered form or its loss, absent from normal cells; no corpus medicine is aimed at it yet. HPA TCF3: RNA low tissue specificity; high antibody staining in 5 normal tissues; highest cancer staining colorectal cancer (3 of 10 high). Distribution: 3 cancer families in the corpus carry a prevalence row, label threshold or catalogue link for it (Leukaemia, Lymphoma, Lung cancer (all types)); Open Targets associates it with 0 specific cancer types at or above 0.5. (Rule 6 of scripts/fetch-target-specificity.ts.)
Sources: UniProt P15923; CIViC gene TCF3; Human Protein Atlas TCF3 tissue; Open Targets ENSG00000071564 associations
First described 1989. Earliest sequence paper UniProt cites for the protein: Murre et al, Cell, 1989, "A new DNA binding and dimerization motif in immunoglobulin enhancer binding, daughterless, MyoD, and myc proteins". Source.
Sources: HGNC HGNC:11633 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt P15923 (protein name, function text, keywords and locations (REST API)); CIViC gene TCF3 (1 evidence items, 0 assertions, 1 variants; diseases: Burkitt Lymphoma (GraphQL API, CC0)); Open Targets ENSG00000071564 (association with cancer (MONDO_0004992) 0.65; per-cancer scores at or above 0.5: non-small cell lung carcinoma 0.51, acute lymphoblastic leukaemia 0.58, non-Hodgkin lymphoma 0.61, lung cancer 0.53, leukaemia 0.61 (GraphQL API, CC0))
Transcriptional regulator involved in the initiation of neuronal differentiation and mesenchymal to epithelial transition. Heterodimers between TCF3 and tissue-specific basic helix-loop-helix (bHLH) proteins play major roles in determining tissue-specific cell fate during embryogenesis, like muscle or early B-cell differentiation. Together with TCF15, required for the mesenchymal to epithelial transition. Dimers bind DNA on E-box motifs: 5'-CANNTG-3'. Binds to the kappa-E2 site in the kappa immunoglobulin gene enhancer. Binds to IEB1 and IEB2, which are short DNA sequences in the insulin gene transcription control region. Location: Nucleus (UniProt). Locus 19p13.3 (HGNC).
RNA: low tissue specificity, detected in all normal tissues.
Medium: Appendix, Endometrium, Placenta, Rectum.
Medium only: breast cancer, carcinoid, endometrial cancer, glioma.
Human Protein Atlas version 25.1, antibody staining at reliability approved, enhanced or supported; used under CC BY-SA 3.0. Staining counts are patients per level in the atlas cohort, not population prevalence.
Query for this target: (TITLE:"TCF3" OR ABSTRACT:"TCF3" OR TITLE:"transcription factor 3" OR ABSTRACT:"transcription factor 3" OR TITLE:"Transcription factor E2-alpha" OR ABSTRACT:"Transcription factor E2-alpha" OR TITLE:"E2A" OR ABSTRACT:"E2A" OR TITLE:"ITF1" OR ABSTRACT:"ITF1" OR TITLE:"MGC129647" OR ABSTRACT:"MGC129647") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about TCF3, not a curated reading list.
Shares The cell-cycle engine (cyclins & CDKs), B-cell receptor / BTK signalling (to NF-κB), Burkitt lymphoma, PI3K / AKT / mTOR.
Shares The cell-cycle engine (cyclins & CDKs), B-cell receptor / BTK signalling (to NF-κB), Burkitt lymphoma, PI3K / AKT / mTOR.
Shares Leukaemia (all types), Acute lymphoblastic leukaemia, Lung cancer (all types), Non-Hodgkin lymphoma (all types).
Shares Leukaemia (all types), Acute lymphoblastic leukaemia, CIViC, Non-Hodgkin lymphoma (all types).
Shares Burkitt lymphoma, Leukaemia (all types), Acute lymphoblastic leukaemia, Non-Hodgkin lymphoma (all types).
Shares Burkitt lymphoma, CIViC, Lung cancer (all types), Non-Hodgkin lymphoma (all types).
Shares Leukaemia (all types), Acute lymphoblastic leukaemia, CIViC, Lung cancer (all types).
Shares Leukaemia (all types), Acute lymphoblastic leukaemia, CIViC, Lung cancer (all types).